 |
SuperGen Granted Orphan Drug Designation for MP-470 in Glioblastoma Multiforme
Aug 7, 2008
|
7.3 KB |
|
| |
DUBLIN, Calif., Aug. 7 /PRNewswire-FirstCall/ -- SuperGen, Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced that the U.S. Food and Drug
Administration (FDA) has granted orphan drug designation for the...
|
|
SuperGen Reports 2008 Second Quarter Financial Results
Aug 4, 2008
|
20.0 KB |
|
| |
Quarterly Dacogen Royalty Revenue Increases 76% from Same Prior Year Period
DUBLIN, Calif., Aug. 4 /PRNewswire-FirstCall/ -- SuperGen, Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced finan...
|
|
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Jul 1, 2008
|
8.6 KB |
|
| |
Reiterates 2008 Annual Financial Guidance
DUBLIN, Calif., July 1 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today commented on the preliminary efficacy data
from a...
|
|
SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation
Jun 16, 2008
|
5.4 KB |
|
| |
DUBLIN, Calif., June 16 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced at the 13th Congress of the
European Hematology Association (EHA) in Copenhagen, Denmark, th...
|
|
SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models
Jun 13, 2008
|
6.7 KB |
|
| |
DUBLIN, Calif., June 13, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced at the 13th Congress of the
European Hematology Association (E...
|
|
Astex Announces New Drug Discovery Alliance with Janssen Pharmaceutica N.V.
Jun 9, 2008
|
14.6 KB |
|
| |
Cambridge, UK 9th June, 2008. Astex Therapeutics Limited (“Astex”) today announced that Astex and Janssen Pharmaceutica have entered into a research alliance focused on the research, development and commercialisation of novel drugs for the treatment of cancer. The new agreement grants Janssen Pharmaceutica a worldwide exclusive lic...
|
|
Astex Drug Candidates to be Presented at the 2008 American Society of Clinical Oncology Annual Meeting
May 28, 2008
|
12.8 KB |
|
| |
Cambridge, UK 28th May 2008, Astex Therapeutics Limited announced today that data on two of its drug candidates, AT7519 and AT9283, will be presented at the ASCO Annual Conference, to be held 31st May - 3rd June 2008 in Chicago. Both of these candidates were discovered internally at Astex using its industry-leading fragment-based drug discovery...
|
|
SuperGen Reports 2008 First Quarter Financial Results
Apr 28, 2008
|
14.7 KB |
|
| |
Dacogen Royalty Revenue Increases 114% from Same Prior Year Period
DUBLIN, Calif., April 28 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG) today reported financial results for the first quarter ended
March 31, 2008.
Total revenues for the 2008 first quarter were $8.1 million, compared with
$4.4 million for the ...
|
|
Royal Society of Chemistry recognises Astex Scientists
Apr 22, 2008
|
11.0 KB |
|
| |
Cambridge, UK, 22nd April 2008. Astex Therapeutics announced today that Dr. Harren Jhoti, Founder and CEO and Dr. David Rees, VP Medicinal Chemistry, have both been recognised with prestigious awards from the Royal Society of Chemistry (RSC). The RSC is the largest organisation in Europe for advancing the chemical sciences.
Dr. Harren ...
|
|
SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008
Apr 22, 2008
|
3.8 KB |
|
| |
DUBLIN, Calif., April 22 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, invites all interested parties to listen and view
a live webcast of its 3rd Annual Analyst Day beginning at...
|
|
SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, that Causes Tumor Regression in AML Xenograft Models
Apr 16, 2008
|
5.3 KB |
|
| |
DUBLIN, Calif., April 16, 2008 - SuperGen Inc. (Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies, today announced as part of a series of presentations at the 2008 AACR Annual Meeting that that it has identified a lead PIM kinas...
|
|
Data Show SuperGen's MP-470 is Safe in Humans
Apr 15, 2008
|
6.3 KB |
|
| |
DUBLIN, Calif., April 15 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced as part of a series of
presentations at the 2008 AACR Annual Meeting that MP-470, its clini...
|
|
SuperGen's MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib
Apr 14, 2008
|
5.4 KB |
|
| |
Data support MP-470's role in overcoming erlotinib resistance
DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced as part of a serie...
|
|
Astex Drug Candidates to be Presented at the 2008 AACR Annual Meeting
Apr 8, 2008
|
13.7 KB |
|
| |
Cambridge, UK, 8th April 2008. Astex Therapeutics announced today that data on three of its drug candidates, AT7519, AT9283 and an FGFr kinase inhibitor, will be presented at the 2008 AACR Annual Conference, to be held April 12-16, 2008 in San Diego. All three drug candidates were discovered internally using Astex’s industry-leading frag...
|
|
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting
Apr 7, 2008
|
6.7 KB |
|
| |
DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced that multiple abstracts have been
accepted for oral and poster presentations at the AA...
|
|
SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine
Mar 14, 2008
|
6.0 KB |
|
| |
Restored sensitivity to cisplatin observed in ovarian carcinoma xenografts
DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- SuperGen Inc.
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today announced as pa...
|
|
SuperGen Reports 2007 Fourth Quarter and Annual Financial Results
Mar 3, 2008
|
18.4 KB |
|
| |
Company Achieves 2007 Net Income of $13.1 Million
DUBLIN, Calif., March 3 /PRNewswire-FirstCall/ -- SuperGen Inc.,
(Nasdaq: SUPG), a pharmaceutical company dedicated to the discovery, rapid
development and commercialization of therapies for solid tumors and
hematological malignancies, today reported financial results for the fourt...
|
|
Astex Receives IND Approval for its Small Molecule HSP90 Inhibitor AT13387; Astex Announces Extension of Drug Discovery Alliance
Feb 6, 2008
|
11.6 KB |
|
| |
Astex Therapeutics announced today that it has received approval of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for AT13387, a selective small molecule inhibitor of Heat Shock Protein 90 (Hsp90) to treat cancer. This is the third IND candidate from Astex’s internal discovery and developm...
|
|
SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Dec 17, 2007
|
6.7 KB |
|
| |
DUBLIN, Calif., December 17 /PRNewswire-FirstCall/ -- SuperGen, Inc.
(Nasdaq: SUPG) today announced that investigators have dosed the first patient
in a multi-arm Phase 1b clinical trial of MP470, a novel, oral, multi-targeted
tyrosine kinase inhibitor (TKI). The trial will evaluate MP470 in combination
with several standard of care chemothe...
|
|
Data Indicate That SuperGen's Lead JAK2 Kinase Inhibitors Prevent Cancer Cell Proliferation in Non-clinical Models
Dec 10, 2007
|
6.1 KB |
|
| |
ATLANTA, Dec. 10 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG), a
pharmaceutical company dedicated to the discovery, rapid development and
commercialization of therapies for solid tumors and hematological
malignancies, today announced the presentation of data that describe how its
lead JAK2 kinase inhibitors prevent cancer cell prol...
|
|
|
Delicious
Digg
Facebook
LinkedIn
Twitter